Related Experiment Video
Updated: May 23, 2026
10:24
A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
Published on: January 27, 2026
Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization
Myles B C Dillon1, Daniel A Bachovchin, Steven J Brown
1Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California 92037, United States.
ACS Chemical Biology
|April 18, 2012
Summary
Researchers developed a novel assay to find selective inhibitors for Protein Arginine Methyltransferase 1 (PRMT1), a key enzyme in cellular processes. This new method identified two promising PRMT1-specific compounds.
Area of Science:
- Biochemistry
- Molecular Biology
- Enzymology
Background:
- Protein arginine methyltransferases (PRMTs) are enzymes catalyzing arginine methylation using S-adenosylmethionine (SAM).
- PRMTs play crucial roles in RNA splicing, transcriptional control, signal transduction, and DNA repair.
- PRMT1 accounts for over 85% of cellular arginine methyltransferase activity, making it a significant target.
Purpose of the Study:
- To develop a selective high-throughput screening (HTS) assay for PRMT1.
- To identify novel, specific inhibitors of PRMT1 with improved properties compared to existing ones.
- To address the limitations of current PRMT1 inhibitors, including lack of specificity, efficacy, and bioavailability.
Main Methods:
- Developed an HTS assay for PRMT1 utilizing a unique hyper-reactive cysteine in its active site.
- Employed a fluorescence polarization method to monitor the kinetics of PRMT1 labeling by a cysteine-reactive probe.
- Screened for inhibitors that selectively target PRMT1 over other SAM-dependent methyltransferases.
Main Results:
- Successfully established a robust HTS assay for PRMT1.
- Identified two novel chemical compounds that exhibit selectivity for PRMT1.
- The identified inhibitors demonstrate potential for targeting PRMT1 specifically.
Conclusions:
- The developed HTS assay provides a valuable tool for discovering PRMT1-specific inhibitors.
- The newly identified inhibitors represent promising leads for further research and therapeutic development.
- Targeting PRMT1 with specific inhibitors could offer significant research and clinical benefits.
